NEW YORK (GenomeWeb News) – BioChain has licensed Epigenomics' methylated Septin9 biomarker for the detection of colorectal cancer and will start offering an assay based on the marker in China, Epigenomics announced today.

BioChain will offer the assay through its Beijing-based independent reference laboratory — equivalent to a CLIA lab — called Beijing BioChain Medical Laboratory. BioChain manufactures life science tools and molecular genetics diagnostics and has offices in Newark, Calif., and Beijing.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.